Prior approval of independent non-executive directors
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), and the governance standards for listed companies issued by the China Securities Regulatory Commission The guiding opinions on the establishment of independent director system in listed companies and other laws and regulations, as well as the relevant provisions of the articles of association of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. and the independent non-executive director system of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd, As an independent non-executive director of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”), After reviewing the relevant materials on the equity incentive plan for directors and core managers of Shanghai Fosun Health Technology (Group) Co., Ltd. (hereinafter referred to as “Fosun health”) (hereinafter referred to as “the plan”) to be submitted to the 65th meeting of the 8th board of directors for deliberation, we hereby express the following opinions:
The plan complies with the company law, the securities law, the stock listing rules of Shanghai Stock Exchange, the Securities Listing Rules of the stock exchange of Hong Kong Limited and other relevant provisions, and the relevant pricing is fair and reasonable.
Since the incentive objects of the plan include the directors / senior managers of the company and several directors and supervisors of Fosun health, according to the provisions of the stock listing rules of Shanghai Stock Exchange and the Securities Listing Rules of the stock exchange of Hong Kong Limited, the relevant incentive objects constitute the related parties or connected persons of the company Its participation in the plan constitutes a connected / connected transaction of the company. This connected / connected transaction does not harm the interests of the company and its shareholders, especially the minority shareholders. It is agreed to submit the plan (including this connected / connected transaction) to the board of directors of the company for deliberation.
Independent non-executive directors: Li Ling, Tang Guliang, Wang Quandi, Yu Zishan February 8, 2002
